You may experience temporarily intensified side effects, particularly GI symptoms, but these are typically mild and self-limiting
It may also worsen your condition if you have pancreatitis
It is dosed at 250 mcg to 500 mcg daily, either subcutaneously or through an intranasal applicator
Primary endpoint (CDR-SB): Clearly negative, with no hint of signal or trend
Emerging therapeutic strategies targeting lactate metabolism, including glycolytic inhibition, lactate transporter blockade, combination with immune checkpoint inhibitors, and epigenetic modulation, such as Kla enzyme inhibitors, could potentially aid in subverting the immunosuppressive TME, augmenting immune infiltration, and potentiating chemotherapeutic efficacy (22, 23)
Sinyukhin, A